Abstract
Parenteral administration of the serotonin-1 agonist eltoprazine (0.0625 to 4.0 mg/kg [0.0002 to 0.016 mmol/kg]) in freely moving cats produced significant supression of electrophysiologic rapid eye movement (REM) sleep signs, ponto-geniculo-occipital (PGG) activity, and REM sleep behavior. The virtual total suppression of REM sleep (0.4%, 4.0 mg/kg) and PGO wave activity (2 to 4 mg/kg) in exchange for increasing amounts of non-REM (NREM) slow-wave sleep was a dose-dependent function of the amount of eltoprazine administered. Wakefulness was unaffected by eltoprazine regardless of dose. Concurrent with this dose-dependent suppression of REM was a dose-dependent increase in electroencephalographic synchrony and mean electromyographic amplitude. Since eltoprazine was found to shift the balance between REM and NREM sleep but did not change the balance between sleep and waking, it is a potentially useful tool for the investigation of serotonergic-cholinergic interaction.
Similar content being viewed by others
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Quattrochi, J., Mamelak, A., Binder, D. et al. Dose-Related Suppression of REM Sleep and PGO Waves by the Serotonin-1 Agonist Eltoprazine. Neuropsychopharmacol 8, 7–13 (1993). https://doi.org/10.1038/npp.1993.2
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/npp.1993.2
Keywords
This article is cited by
-
Inhibition of REM sleep by ipsapirone, A 5HT1A agonist, in normal volunteers
Psychopharmacology (1994)